Search alternatives:
larger decrease » marked decrease (Expand Search)
less decrease » teer decrease (Expand Search), we decrease (Expand Search), levels decreased (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
Showing 321 - 340 results of 4,625 for search 'significantly ((((((less decrease) OR (larger decrease))) OR (nn decrease))) OR (mean decrease))', query time: 0.55s Refine Results
  1. 321
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 322
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 323
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 324
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 325
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 326
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 327
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 328
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 329
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 330
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 331
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 332
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 333
    Statins induced flatter neuronal somas.

    Statins induced flatter neuronal somas. by Shuk C. Tsoi (21192243)

    Published 2025
    Save to List
    Saved in:
  14. 334
    Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales.

    Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales. by Vincenza Tarantino (182506)

    Published 2024
    Save to List
    Saved in:
  15. 335
    Puriton had the tendency of decreasing expressions of Th1 cell-related cytokines such as IFN-

    Puriton had the tendency of decreasing expressions of Th1 cell-related cytokines such as IFN- by So-Hyeon Bok (8066696)

    Published 2025
    Save to List
    Saved in:
  16. 336
    Forest plots illustrate the mean difference in; (A) creatinine clearance, (B) eGFR, (C) BUN, and (D) shows relative risk in ARF.

    Forest plots illustrate the mean difference in; (A) creatinine clearance, (B) eGFR, (C) BUN, and (D) shows relative risk in ARF. by Mohamed R. Abdelraouf (21501468)

    Published 2025
    Save to List
    Saved in:
  17. 337
    Change in Watt’s Connectedness Scale, Subscales by Treatment Group.

    Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 338
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 339
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 340
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: